Opendata, web and dolomites

Relieve-Chol

Reprogramming cell identity to develop new therapies against Cholangiopathies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Relieve-Chol project word cloud

Explore the words cloud of the Relieve-Chol project. It provides you a very rough idea of what is the project "Relieve-Chol" about.

bypass    molecules    discovery    differentiate    generate    despite    bile    transplantation    cells    hepatic    vivo    patients    hepatocytes    cholangiocytes    pluripotent    direct    cholangiopathies    form    stage    protocol    diversity    differentiated    therapies    genetic    consequently    relevance    small    maintaining    culture    acid    modification    quantity    rarely    models    stem    therapeutics    biliary    recapitulate    biopsy    liver    clinical    almost    grown    disease    entire    modeling    proliferate    transport    display    ing    animal    purposes    indefinitely    fibrosis    industry    fulfill    capacity    validate    line    loosing    platform    functional    urgent    vitro    pathophysiology    disorders    interestingly    tract    somatic    chemically    create    reprograming    transformed    drug    diseases    hipscs    intra    functions    human    pharmaceutical    hipsc    cure    types    cell    solution    primary    counterpart    compatible    cystic    screening    advantageous   

Project "Relieve-Chol" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙907 €
 EC max contribution 149˙907 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 149˙907.00

Map

 Project objective

Intra- hepatic Cholangiocytes represent one of the main cell type of the liver with hepatocytes. They line the biliary tract and fulfill essential functions such as bile modification and transport. Cholangiocytes are targeted by a diversity of diseases including genetic disorders such as Cystic Fibrosis. There is currently no cure for disorders affecting cholangiocytes and end stage disease require liver transplantation. Importantly, primary cholangiocytes obtained from biopsy can not be grown in vitro without loosing their functional characteristics while transformed cells and animal models rarely recapitulate the entire pathophysiology of human diseases. Consequently, the development of novel drug and therapies remains problematic despite an urgent clinical need. Human induced pluripotent stem cells could provide an advantageous solution to bypass this major challenge. Indeed, these pluripotent stem cells are generated by direct reprograming of somatic cells and they can proliferate almost indefinitely in vitro while maintaining their capacity to differentiate into almost any cell types. Interestingly, hIPSC can be derived from patients with genetic disorders and then differentiated into the relevant cell types for disease modeling purposes. Of direct interest, we recently developed a protocol to generate cholangiocytes from hIPSCs using chemically define conditions. The resulting cells display functional characteristics of their in vivo counterpart including the capacity to transport bile acid. Here, we propose to enable our culture system for the production of large quantity of hIPSCs derived cholangiocytes in conditions compatible with the pharmaceutical industry requirements. The resulting cells will be then fully characterized to validate their relevance for modeling Cystic fibrosis and for testing small molecules. Thus, the overall objective of this project is to create a novel drug screening platform for the discovery of therapeutics targeting genetic form of cholangiopathies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RELIEVE-CHOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RELIEVE-CHOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

CARBYNE (2020)

New carbon reactivity rules for molecular editing

Read More  

PonD (2019)

Particles-on-Demand for Multiscale Fluid Dynamics

Read More